The minimum element of a synthetic peptide required to block prostate tumor cell migration
暂无分享,去创建一个
[1] A. Cress,et al. Synthetic D-amino acid peptide inhibits tumor cell motility on laminin-5. , 2006, Carcinogenesis.
[2] T. Kawaguchi. Cancer metastasis: characterization and identification of the behavior of metastatic tumor cells and the cell adhesion molecules, including carbohydrates. , 2005, Current drug targets. Cardiovascular & haematological disorders.
[3] K. Lam,et al. The use of a combinatorial library method to isolate human tumor cell adhesion peptides , 1996, Molecular Diversity.
[4] Jer-Tsong Hsieh,et al. The role of cell adhesion molecule in cancer progression and its application in cancer therapy. , 2004, Acta biochimica Polonica.
[5] S. Hibino,et al. Identification of an Active Site on the Laminin α5 Chain Globular Domain That Binds to CD44 and Inhibits Malignancy , 2004, Cancer Research.
[6] H. Jin,et al. Integrins: roles in cancer development and as treatment targets , 2004, British Journal of Cancer.
[7] H. Oettle,et al. Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. , 2004, Oral oncology.
[8] K. Lam,et al. Synthesis of hydrophilic and flexible linkers for peptide derivatization in solid phase. , 2004, Bioorganic & medicinal chemistry letters.
[9] S. Hibino,et al. Identification of a potent peptide antagonist to an active laminin-1 sequence that blocks angiogenesis and tumor growth. , 2003, Cancer research.
[10] H. Kleinman,et al. The basement membrane matrix in malignancy , 2003, The Journal of pathology.
[11] G. Tucker. Alpha v integrin inhibitors and cancer therapy. , 2003, Current opinion in investigational drugs.
[12] K. Lam,et al. Applications of one-bead one-compound combinatorial libraries and chemical microarrays in signal transduction research. , 2003, Accounts of chemical research.
[13] Lee M Ellis,et al. Alphavbeta3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. , 2003, Cancer research.
[14] J. Verweij,et al. Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. , 2003, European journal of cancer.
[15] Jeffrey W. Smith. Cilengitide Merck. , 2003, Current opinion in investigational drugs.
[16] Richard O Hynes,et al. Integrins Bidirectional, Allosteric Signaling Machines , 2002, Cell.
[17] I. Macdonald,et al. Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.
[18] Lee Makowski,et al. One from column A and two from column B: the benefits of phage display in molecular-recognition studies. , 2002, Current opinion in chemical biology.
[19] David A. Cheresh,et al. Role of integrins in cell invasion and migration , 2002, Nature Reviews Cancer.
[20] Kit S Lam,et al. Therapeutic cancer targeting peptides. , 2002, Biopolymers.
[21] S. Mousa,et al. The alpha v integrin antagonists as novel anticancer agents: an update. , 2002, Expert opinion on investigational drugs.
[22] K. Lamborn,et al. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. , 2002, Cancer research.
[23] R. Benjamin,et al. Pilot study of vitaxin—an angiogenesis inhibitor—in patients with advanced leiomyosarcomas , 2001, Cancer.
[24] K. Lam,et al. Synthetic peptides inhibit adhesion of human tumor cells to extracellular matrix proteins. , 2001, Cancer research.
[25] J. Posey,et al. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer. , 2001, Cancer biotherapy & radiopharmaceuticals.
[26] P. Grieco,et al. Preparation of 'side-chain-to-side-chain' cyclic peptides by Allyl and Alloc strategy: potential for library synthesis. , 2001, The journal of peptide research : official journal of the American Peptide Society.
[27] K. Mikecz. Vitaxin applied molecular evolution. , 2000, Current opinion in investigational drugs.
[28] T. N. Campbell,et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] I. Macdonald,et al. Clinical targets for anti-metastasis therapy. , 2000, Advances in cancer research.
[30] R. Nagle,et al. N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion withStromal cells. , 1999, The American journal of pathology.
[31] N. Fusenig,et al. Epidermal differentiation and basement membrane formation by HaCaT cells in surface transplants. , 1998, European journal of cell biology.
[32] M. Nomizu,et al. Activation of β1 Integrin Signaling Stimulates Tyrosine Phosphorylation of p190 RhoGAP and Membrane-protrusive Activities at Invadopodia* , 1998, The Journal of Biological Chemistry.
[33] H. Kleinman,et al. Liver metastasis formation by laminin‐1 peptide (LQVQLSIR)‐adhesion selected B16‐F10 melanoma cells , 1997, International journal of cancer.
[34] Kit S. Lam,et al. The "One-Bead-One-Compound" Combinatorial Library Method. , 1997, Chemical reviews.
[35] I. Rabinovitz,et al. The integrin alpha 6 beta 4 and the biology of carcinoma. , 1996, Biochemistry and cell biology = Biochimie et biologie cellulaire.
[36] A. Utani,et al. Identification of Cell Binding Sites in the Laminin α1 Chain Carboxyl-terminal Globular Domain by Systematic Screening of Synthetic Peptides (*) , 1995, The Journal of Biological Chemistry.
[37] K. Friedrichs,et al. High expression level of alpha 6 integrin in human breast carcinoma is correlated with reduced survival. , 1995, Cancer research.
[38] R. Nagle,et al. The alpha 6 beta 1 and alpha 6 beta 4 integrins in human prostate cancer progression. , 1995, Cancer metastasis reviews.
[39] H. Kleinman,et al. The laminin alpha 1 chain Ile-Lys-Val-Ala-Val (IKVAV)-containing peptide promotes liver colonization by human colon cancer cells. , 1995, Cancer research.
[40] M. Rothmund,et al. Expression and Distribution of VLA Receptors in the Pancreas: An Immunohistochemical Study , 1993, Pancreas.
[41] M. Rothmund,et al. Expression and function of VLA-alpha 2, -alpha 3, -alpha 5 and -alpha 6-integrin receptors in pancreatic carcinoma. , 1992, International journal of cancer.
[42] T. Carey,et al. Culture conditions affect expression of the alpha 6 beta 4 integrin associated with aggressive behavior in head and neck cancer. , 1992, Advances in experimental medicine and biology.
[43] Kit S. Lam,et al. A new type of synthetic peptide library for identifying ligand-binding activity , 1992, Nature.
[44] A. Skubitz,et al. Synthetic peptides from the carboxy-terminal globular domain of the A chain of laminin: their ability to promote cell adhesion and neurite outgrowth, and interact with heparin and the beta 1 integrin subunit , 1991, The Journal of cell biology.
[45] R. Barrett,et al. Peptides on phage: a vast library of peptides for identifying ligands. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[46] J. Devlin,et al. Random peptide libraries: a source of specific protein binding molecules. , 1990, Science.
[47] E. Ruoslahti,et al. Inhibition of in vitro tumor cell invasion by Arg-Gly-Asp-containing synthetic peptides [published erratum appears in J Cell Biol 1989 Jun;108(6):following 2546] , 1988, The Journal of cell biology.
[48] H. Kleinman,et al. YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. , 1987, Science.
[49] E Ruoslahti,et al. New perspectives in cell adhesion: RGD and integrins. , 1987, Science.
[50] M. Humphries,et al. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. , 1986, Science.
[51] Erkki Ruoslahti,et al. Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule , 1984, Nature.
[52] E. Kaiser,et al. Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides. , 1970, Analytical biochemistry.